Articles

Do not manage the clock. Manage the risk.

FDA’s one-day inspectional assessments are not a shorter inspection. They are a faster decision about whether your site deserves a longer one.

3 min read

The FDA Commissioner talked about one-day inspections. Let us not get this twisted.

FDA is not saying inspections are now one-day inspections. That is the wrong way to read the announcement. This is not really about FDA being on site for only one day. It is about FDA deciding quickly whether your site deserves a deeper look.

So please do not read this announcement and then try to justify (dear clients) why a one-day audit is feasible for your high-risk facility. That is not what this is.

If your site is complex, sterile, biologic, device-related, recently changed, previously inspected with findings, or carrying significant quality risk, you should not be planning around “one day”. You should be planning around your actual risk profile.

What the numbers actually said

FDA reported that approximately 46 of these one-day assessments had been completed, with most resulting in No Action Indicated outcomes. On the surface that may sound positive. But another fair question is whether a one-day assessment is deep enough to uncover meaningful problems.

Many serious GMP issues are not obvious in one day. Weak investigations, poor CAPA effectiveness, incomplete validation, poor data integrity practices, recurring deviations and ineffective quality oversight usually require time, document review, interviews and system tracing.

What one day is absolutely enough for

That said, one thing FDA can see very quickly is the facility.

In one day, an investigator can observe:

  • the condition of the building
  • cleanroom flow, gowning flow, material flow
  • equipment condition, utilities, maintenance practices
  • housekeeping, segregation, contamination-control risks
  • and whether the facility appears to support the operations being performed

These are visible signals. They may not tell the whole story, but they can quickly shape an investigator’s view of the site’s state of control.

Vioela’s note: An experienced investigator forms a working theory of a site in the first hour, mostly from things nobody rehearsed. Look up: stained ceiling tiles and condensation mean water is going where it should not. Look down: drains, damaged flooring, pooled water. Look at the equipment: status tags with dates that do not add up, calibration stickers past due, logbooks filled in suspiciously neat blocks. Look in the bins, because discarded raw data found in a waste basket has started many a data integrity case. And notice where the tour does not go. The reject cage, the retain room and the back of the warehouse say more about a quality system than the conference room does.

The better question

That is why companies should not respond to this pilot by asking, “How do we manage FDA for one day?”

The better question is:

What could FDA see in one day that would cause them to stay longer, expand the scope, or come back for a fuller inspection?

Look at your site the way an experienced facility and manufacturing reviewer would look at it: layout, utilities, cleanroom design, personnel and material flow, equipment condition, maintenance history, contamination control, and whether the physical facility still supports the validated state.

The practical message is simple: do not manage the clock; manage the risk. If the facility sends the wrong signal on day one, the inspection can become much more serious very quickly.

Vioela’s note: Two practical points about how these visits end. A short assessment can still close with a Form FDA 483, and the clock that matters starts there: a written response received within 15 business days is considered before the agency decides whether to escalate. And “No Action Indicated” is a classification of that visit, not a clean bill of health for the site. It describes what one investigator saw in the time available.

Adapted from a post first published on LinkedIn.